ATE339446T1 - Modifizierter humaner granulozyten makrophagen kolonien stimulierender faktor (gm-csf) mit reduzierter immunogenität - Google Patents

Modifizierter humaner granulozyten makrophagen kolonien stimulierender faktor (gm-csf) mit reduzierter immunogenität

Info

Publication number
ATE339446T1
ATE339446T1 AT02732448T AT02732448T ATE339446T1 AT E339446 T1 ATE339446 T1 AT E339446T1 AT 02732448 T AT02732448 T AT 02732448T AT 02732448 T AT02732448 T AT 02732448T AT E339446 T1 ATE339446 T1 AT E339446T1
Authority
AT
Austria
Prior art keywords
csf
stimulating factor
granulocyte macrophage
human granulocyte
modified human
Prior art date
Application number
AT02732448T
Other languages
English (en)
Inventor
Francis J Carr
Graham Carter
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of ATE339446T1 publication Critical patent/ATE339446T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT02732448T 2001-03-08 2002-02-28 Modifizierter humaner granulozyten makrophagen kolonien stimulierender faktor (gm-csf) mit reduzierter immunogenität ATE339446T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01105775 2001-03-08

Publications (1)

Publication Number Publication Date
ATE339446T1 true ATE339446T1 (de) 2006-10-15

Family

ID=8176721

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02732448T ATE339446T1 (de) 2001-03-08 2002-02-28 Modifizierter humaner granulozyten makrophagen kolonien stimulierender faktor (gm-csf) mit reduzierter immunogenität

Country Status (15)

Country Link
US (1) US7208147B2 (de)
EP (1) EP1366074B1 (de)
JP (1) JP2004535777A (de)
KR (1) KR20030082962A (de)
CN (1) CN1494551A (de)
AT (1) ATE339446T1 (de)
BR (1) BR0207945A (de)
CA (1) CA2439926A1 (de)
DE (1) DE60214682T2 (de)
HU (1) HUP0303429A3 (de)
MX (1) MXPA03008032A (de)
PL (1) PL362986A1 (de)
RU (1) RU2003129058A (de)
WO (1) WO2002070548A2 (de)
ZA (1) ZA200307829B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022593A2 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
AU2013201228B2 (en) * 2006-02-08 2016-01-21 Eisai, Inc. Antigenic gm-csf peptides and antibodies to gm-csf
KR101395515B1 (ko) 2006-02-08 2014-05-14 모르포테크, 인크. 항원성 gm-csf 펩티드 및 gm-csf에 대한 항체
US20090010966A1 (en) * 2007-06-21 2009-01-08 Angelica Therapeutics, Inc. Modified diphtheria toxins
EP2268297A4 (de) * 2008-02-29 2011-11-16 Angelica Therapeutics Inc Modifizierte toxine
US9493515B2 (en) 2011-11-29 2016-11-15 Proclara Biosciences, Inc. Bacteriophage gene 3 protein compositions and use as amyloid binding agents
EA033666B1 (ru) 2012-10-02 2019-11-14 Proclara Biosciences Inc Амилоидсвязывающие белки и их применение
EP2968450A4 (de) 2013-03-15 2016-10-26 Angelica Therapeutics Inc Modifizierte toxine
JP2016526044A (ja) 2013-05-28 2016-09-01 ニューロファージ ファーマシューティカルズ, インコーポレイテッド 低減された免疫原性を有する修飾されたバクテリオファージg3pアミノ酸配列を含むポリペプチド
KR20170085132A (ko) 2014-12-03 2017-07-21 프로클라라 바이오사이언시즈, 인크. 글리코실화 신호가 결핍된 변형된 박테리오파지 g3p 아미노산 서열을 포함하는 폴리펩티드
TW201808987A (zh) 2016-06-08 2018-03-16 健生生物科技公司 Gm-csf變體及使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5349052A (en) * 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
EP0983303B1 (de) * 1997-05-21 2006-03-08 Biovation Limited Verfahren zur herstellung von nicht-immunogenen proteinen
GB9712892D0 (en) * 1997-06-20 1997-08-20 Eclagen Ltd Identification of mhc binding peptides
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity

Also Published As

Publication number Publication date
WO2002070548A2 (en) 2002-09-12
WO2002070548A3 (en) 2003-05-01
EP1366074A2 (de) 2003-12-03
CA2439926A1 (en) 2002-09-12
ZA200307829B (en) 2004-07-21
MXPA03008032A (es) 2003-12-04
HUP0303429A3 (en) 2005-12-28
JP2004535777A (ja) 2004-12-02
HUP0303429A2 (hu) 2004-01-28
US7208147B2 (en) 2007-04-24
PL362986A1 (en) 2004-11-15
DE60214682T2 (de) 2007-09-13
DE60214682D1 (de) 2006-10-26
RU2003129058A (ru) 2005-04-20
BR0207945A (pt) 2004-07-27
KR20030082962A (ko) 2003-10-23
EP1366074B1 (de) 2006-09-13
US20040092717A1 (en) 2004-05-13
CN1494551A (zh) 2004-05-05

Similar Documents

Publication Publication Date Title
WO2002074783A3 (en) Modified interferon beta with reduced immunogenicity
WO2002062832A3 (en) Modified human brain-derived neutrophic factor (bdnf) with reduced immunogenicity
DE60214682D1 (de) Modifizierter humaner granulozyten makrophagen kolonien stimulierender faktor (gm-csf) mit reduzierter immunogenität
IL212076A (en) Isolated polypeptides of ifn – a method for their preparation, medicinal preparations containing them and their use in the preparation of drugs for treatment with interferon
HUP0401534A2 (hu) Módosított humán IX. faktor
WO2002085941A3 (en) Modified interferon alpha with reduced immunogenicity
WO2002062843A3 (en) Modified erythropoietin (epo) with reduced immunogenicity
AU2210899A (en) Use of a phosphatidylserine/polypeptide conjugate for inducing autoimmunity in the treatment of cancers
WO2000055345A3 (en) Therapy of cancer by insect cells containing recombinant baculovirus encoding genes
EA200100939A1 (ru) Продолжительно действующие инсулинотропные пептиды
NZ516381A (en) Lung tumor proteins in the therapy and diagnosis of lung cancer
WO2003040398A3 (en) Proteins stabilized with polysaccharide gums
WO2002062833A3 (en) Modified leptin with reduced immunogenicity
MXPA04005053A (es) Metodos y composiciones para tratar lesiones del epitelio respiratorio.
IS2670B (is) Bóluefni og notkun þar á til meðhöndlunar á blandaðri hreyfitaugahrörnun
WO2002070698A3 (en) Modified ciliary neurotrophic factor (cntf) with reduced immunogenicity
WO2002077034A3 (en) Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity
ATE515258T1 (de) Mukosales verabreichungssytem
PL373795A1 (en) Thymosin alpha 1 peptide/polymer conjugates
DK1173476T3 (da) Funktionelle sojabönneproteiner
BR0207905A (pt) Protamina modificada com imunogenicidade reduzida
WO2003006047A3 (en) Methods for reducing immunogenicity of polypeptides
WO2002068469A3 (en) Modified thrombopoietin with reduced immunogenicity
WO2002074808A3 (en) Modified insulin with reduced immunogenicity
BR0207017A (pt) Fator de crescimento ceratinócito modificado (kgf) com imunogenicidade reduzida

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties